Modifying the acute inflammatory response has wide clinical benefits. Current options include non-steroidal anti-inflammatory drugs (NSAIDs) and therapies that may resolve inflammation. Acute inflammation involves multiple cell types and various processes. We, therefore, investigated whether an immunomodulatory drug that acts simultaneously at multiple sites shows greater potential to resolve acute inflammation more effectively and with fewer side effects than a common anti-inflammatory drug developed as a small molecule for a single target. In this work, we used time-series gene expression profiles from a wound healing mouse model to compare the effects of Traumeel (Tr14), a multicomponent natural product, to diclofenac, a single component NSAID on inflammation resolution. We advance previous studies by mapping the data onto the “Atlas of Inflammation Resolution”, followed by in silico simulations and network analysis. We found that Tr14 acts primarily on the late phase of acute inflammation (during resolution) compared to diclofenac, which suppresses acute inflammation immediately after injury. Our results provide new insights how network pharmacology of multicomponent drugs may support inflammation resolution in inflammatory conditions.

中文翻译：

---

网络分析揭示了多组分 Tr14 与单组分双氯芬酸在急性炎症模型中的作用的新见解

改变急性炎症反应具有广泛的临床益处。目前的选择包括非甾体类抗炎药 (NSAID) 和可以解决炎症的疗法。急性炎症涉及多种细胞类型和各种过程。因此，我们研究了一种同时作用于多个位点的免疫调节药物是否比作为针对单个靶点的小分子开发的普通抗炎药更有效地解决急性炎症并具有更少的副作用。在这项工作中，我们使用来自伤口愈合小鼠模型的时间序列基因表达谱来比较多组分天然产物 Traumeel (Tr14) 与单组分 NSAID 双氯芬酸对炎症消退的影响。我们通过将数据映射到“炎症分辨率图集”，然后进行计算机模拟和网络分析来推进以前的研究。我们发现，与双氯芬酸相比，Tr14 主要作用于急性炎症的晚期（消退期间），双氯芬酸在受伤后立即抑制急性炎症。我们的结果提供了多组分药物的网络药理学如何支持炎症条件下炎症消退的新见解。